ERBB2 and ductal breast carcinoma in situ: HER2 expression is shown to be dependent upon Notch signaling in BCSCs: Farnie et al.[106] obtained promising results by combining therapies targeting Notch and HER2, respectively, in ductal carcinoma in situ stem cells.